1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 2,225 | 2,320 | 22:56 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 27.10. | Theradiag: Downward Adjustment of the Sales and Profitability Targets For 2026 | 258 | Business Wire | Regulatory News:
THERADIAG (ISIN: FR0004197747, Ticker: ALTER), a company specializing in in vitro diagnostics and Theranostics, is adjusting its 2026 sales and profitability targets.
During... ► Artikel lesen | |
| 30.09. | Theradiag: Appointment of an Independent Expert | 283 | Business Wire | Regulatory News:
THERADIAG (ISIN: FR0004197747, Ticker: ALTER) (Paris:ALTER), a company specializing in in vitro diagnostics and Theranostics, announces the appointment of Crowe HAF by the Company's... ► Artikel lesen | |
| 23.09. | Theradiag Announces That Biosynex Has Filed a Voluntary Takeover Bid for Its Shares | 596 | Business Wire | Regulatory News:
THERADIAG (ISIN: FR0004197747, Ticker: ALTER) (Paris:ALTER), a company specializing in in vitro diagnostics and Theranostics, announces that Biosynex (ISIN: FR0011005933 Mnemonic:... ► Artikel lesen | |
| 19.09. | Theradiag Announces Its Results for the First Half of 2022: Breaking-Even and Confirming Its Ability to Be Structurally Profitable From Early 2023 | 312 | Business Wire | Regulatory News:
THERADIAG (ISIN: FR0004197747, Ticker: ALTER), a company specializing in in vitro diagnostics and Theranostics, today announces its half-year results to June 30, 2022, as approved... ► Artikel lesen | |
| THERADIAG Aktie jetzt für 0€ handeln | |||||
| 18.07. | Theradiag Reports Revenue of €6.3 Million for the First Half of 2022, Up 14.3% | 382 | Business Wire | Solid growth of 9.3% for Theranostics Strong growth of 19.3% in IVD (In Vitro Diagnostics) activity Cash position of €6.0 million on June 30, 2022, in line with the budget
Regulatory... ► Artikel lesen | |
| 08.06. | Quotient Limited and Theradiag Announce Partnership to Advance Autoimmune Disease Diagnostics | 454 | Business Wire | Partnership brings together novel technology and clinical applications expertise to produce automated, multiplexed solutions for advancing autoimmune diagnostics Expands access to $2 billion... ► Artikel lesen | |
| 31.05. | THERADIAG Announces the Launch of ez-Track1, a Point-of-Care Testing Solution for Therapeutic Drug Monitoring | 306 | Business Wire | Regulatory News:
THERADIAG (ISIN: FR0004197747, Mnemonic: ALTER), a company specializing in in vitro diagnostics and theranostics, announces the launch of ez-Track1, a real Point-of-Care Testing... ► Artikel lesen | |
| 19.05. | Theradiag Announces the Launch of Two New i-Tracker Kits | 340 | Business Wire | Regulatory News:
THERADIAG (Paris:ALTER) (ISIN: FR0004197747, Ticker: ALTER), a company specializing in in vitro diagnostics and Theranostics, today announces the launch of two additional kits... ► Artikel lesen | |
| 06.05. | Theradiag: Report of the Ordinary and Extraordinary General Meeting of 5 May 2022 | 257 | Business Wire | New terms of office for Mr Pierre MORGON as Director and Chairman of the Board of directors Appointment of Mr Larry ABENSUR, Mr Thomas LAMY and Mr Thierry PAPER as new directors
Regulatory... ► Artikel lesen | |
| 30.03. | Theradiag: Change in the Composition of the Board of Directors to Be Voted on at the Annual General Meeting of May 5, 2022 | 265 | Business Wire | Regulatory News:
THERADIAG (ISIN: FR0004197747, Ticker: ALTER), a company specializing in in vitro diagnostics and theranostics, today announced that a change in the composition of its Board of... ► Artikel lesen | |
| 21.03. | Theradiag Announces Its 2021 Full-Year Results | 360 | Business Wire | Revenue growth of 6.8%, driven by the solid performance of Theranostics, up 13% 2021 net result of €767 thousand, impacted by exceptional expenses of €496 thousand H2 2021 net result... ► Artikel lesen | |
| 31.01. | Theradiag: THERADIAG Posts 2021 Revenue of €11.1 Million, up 7% | 286 | Business Wire | Excellent performance for Theranostics sales, up 13% Further expansion in activity in the United States, with growth of 17% Growth in the Company's historical IVD activity Cash... ► Artikel lesen | |
| 13.01. | Theradiag: Signing of a Distribution Agreement with BIOSYNEX of Their AMPLIQUICK SARS-CoV-2 PCR Test | 465 | Business Wire | Regulatory News:
THERADIAG (ISIN: FR0004197747, Mnémonique: ALTER), a company specializing in in vitro diagnostics of autoimmune diseases and theranostics, and BIOSYNEX (ISIN: FR0011005933, Mnémonique:... ► Artikel lesen | |
| 08.12.21 | THERADIAG Announces Its 2022 Financial Calendar | 327 | Business Wire | Regulatory News:
THERADIAG (Paris:ALTER) (ISIN: FR0004197747, Ticker: ALTER), a company specializing in in vitro diagnostics of autoimmune diseases and theranostics, today announces its schedule... ► Artikel lesen | |
| 02.12.21 | THERADIAG Announces the Launch of 4 New i-Tracker Kits and the Validation of a New Parameter in the United States | 320 | Business Wire | Regulatory News:
THERADIAG (ISIN: FR0004197747, Ticker: ALTER) (Paris:ALTER), a company specializing in in vitro diagnostics and Theranostics, today announces the launch of four additional kits... ► Artikel lesen | |
| 30.11.21 | Theradiag: THERADIAG notes the acquisition of a stake in its capital by BIOSYNEX | 440 | Business Wire | Regulatory News:
THERADIAG (Paris:ALTER) (ISIN: FR0004197747, Ticker: ALTER), a company specializing in in vitro diagnostics and Theranostics, today announces that it has received yesterday a... ► Artikel lesen |
16 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 47,180 | -0,80 % | Biotech Report: Evotec klettern, Qiagen behauptet | (shareribs.com) Frankfurt 24.11.2022 - Biotech-Aktien zeigen sich am Donnerstag uneinheitlich. Evotec und Vita34 können zulegen, unter Druck liegen derweil Papiere von MorphoSys. An der Wall Street... ► Artikel lesen | |
| AKOUOS | 13,150 | -0,08 % | Akouos, Inc.: Akouos Reports Third Quarter 2022 Financial Results and Provides Business Highlights | -Received clearance from FDA for the AK-OTOF IND application to initiate a Phase 1/2, first in human, pediatric clinical trial -Continued progress toward planned IND submission for AK-antiVEGF... ► Artikel lesen | |
| BIONTECH | 158,20 | +2,20 % | Günstige Ausgangssituationen bei Commerzbank, Desert Gold und BioNTech | Der vermutete Abwärtsdruck aufgrund der Unsicherheiten in Wirtschaft und Geopolitik blieb bisher aus. Vielmehr konnten die wichtigsten Aktienindizes wie DAX oder Dow Jones ihre kurzfristigen Abwärtstrends... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 27,260 | +1,15 % | Vir Biotechnology, Inc.: Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2022 Financial Results | - Biomedical Advanced Research and Development Authority (BARDA) awarded contract to support pandemic preparedness for influenza and other infectious diseases; initial investment of ~$55.0 million... ► Artikel lesen | |
| KARUNA THERAPEUTICS | 223,27 | -0,16 % | Karuna Therapeutics, Inc.: Karuna Therapeutics to Present Data from the Phase 3 EMERGENT-2 Trial of KarXT in Schizophrenia at the 35th European College of Neuropsychopharmacology (ECNP) Congress | Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions... ► Artikel lesen | |
| CINCOR PHARMA | 12,500 | -11,41 % | CinCor downgraded at Oppenheimer after mid-stage setback for blood pressure drug | ||
| ARVINAS | 38,290 | -1,77 % | Arvinas (ARVN) Stock Receives $100 Price Target | ||
| BEAM THERAPEUTICS | 43,610 | +1,00 % | Beam Therapeutics Posts Wider-than-expected Q3 Loss; Stock Down In Pre-market | WASHINGTON (dpa-AFX) - Beam Therapeutics Inc. (BEAM) reported Monday that its third-quarter net loss was $109.6 million or $1.56 per share, compared to last year's loss of $28.1 million or $0.42... ► Artikel lesen | |
| ALLOGENE THERAPEUTICS | 9,290 | -9,45 % | Allogene Therapeutics, Inc.: Allogene Therapeutics Reports Third Quarter 2022 Financial Results and Announces Investor R&D Showcase | Initiated the Industry's First Allogeneic CAR T Phase 2 Trial ALPHA2 Trial, Evaluating ALLO-501A in Relapsed/Refractory Large B Cell Lymphoma Patients, is Designed to Leverage the Ease and Convenience... ► Artikel lesen | |
| PROMETHEUS BIOSCIENCES | 41,540 | -1,42 % | Roche: FDA Okays VENTANA FOLR1 RxDx Assay To Identify Ovarian Cancer Patients Eligible For ELAHERE | SOUTH SAN FRANCISCO (dpa-AFX) - Roche (RHHBY) said Monday that the U.S. Food and Drug Administration approved the VENTANA FOLR1 (FOLR1-2.1) RxDx Assay, the first immunohistochemistry (IHC) companion... ► Artikel lesen | |
| EVOTEC | 16,455 | -2,69 % | Angst wächst - Cardiol Therapeutics, Evotec, Medigene Aktie | Die Angst, nach einer wiederholten Impfung gegen das Coronavirus, etwa durch Injektionen mit den Wirkstoffen von Moderna- und Pfizer/BioNTech, eine Erkrankung an dem Herzen zu bekommen, wächst gerade... ► Artikel lesen | |
| RELAY THERAPEUTICS | 18,270 | -0,76 % | Relay Therapeutics, Inc.: Relay Therapeutics Reports Third Quarter 2022 Financial Results and Corporate Highlights | Shared 88% overall response rate (ORR) from interim data of RLY-4008 in pan-FGFR treatment (FGFRi)-naïve FGFR2-fusion cholangiocarcinoma (CCA) patients treated at the pivotal dose at European Society... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 17,060 | -1,16 % | Arcutis Biotherapeutics, Inc.: Study Showing Significant Improvements in Itch and Itch-Related Sleep Loss with Roflumilast Cream in Adults with Plaque Psoriasis Published in American Journal of Clinical Dermatology | ||
| RECURSION PHARMACEUTICALS | 8,850 | +5,61 % | Recursion Announces $150 Million Private Placement to New and Existing Investors, led by Kinnevik AB | SALT LAKE CITY, Oct. 25, 2022 /PRNewswire/ -- Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, announced today that it... ► Artikel lesen | |
| IMMUNOVANT | 12,700 | -5,22 % | Reasons to Add Immunovant (IMVT) Stock to Your Portfolio Now |
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
